H. Lundbeck A/S (HLUNB) Earnings Call Transcripts
H. Lundbeck A/S's Latest Earnings Call - June 5, 2026
H. Lundbeck A/S's Q2 2026 earnings call focused on the promising results from their Phase IIb PROCEED trial for Bocunebart, a novel migraine treatment. Revenue and earnings details were not disclosed in the transcript. Management highlighted the drug's potential to address unmet needs in chronic migraine, a market estimated to reach over $12 billion by 2031. The company did not provide specific financial guidance changes but indicated a strong pipeline momentum.
Reported metrics
| Metric | Value |
|---|---|
| Monthly Migraine Days Reduction | 1.38 days reduction vs placebo (beat) |
| Chronic Migraine Patient Reduction | 2.3 days reduction vs placebo (beat) |
| Safety Profile | Consistent with previous trials (inline) |
Guidance from management
Lundbeck plans to initiate Phase III trials for Bocunebart in the second half of 2026, focusing on chronic migraine patients. Regulatory discussions are expected to shape the trial design.
What management said
Yes, in that broad range. We have a little bit difference between, of course, HOPE and PROCEED. But proceed was that we were aiming for a maximum of 15% and we got a little less. So somewhat below 15%. .
I can, Johan. And thank you, Kirsty, for the question. We don't see this as a limitation. As Johan just said, this is exactly where the biggest unmet need is. And this is exactly what drives the value. So it is in line with our expectations. And once we are able to share more details on the commercial potential, we do later in the year, it will probably be clearer on why we see the value and what exactly the value is...
What analysts pressed on
Analysts questioned the differentiation of Bocunebart from existing CGRP treatments and its positioning in the treatment paradigm. Concerns were raised about potential cannibalization of Vyepti sales and the efficacy in treatment-resistant populations.
Main topics on the call
- Bocunebart Phase IIb Results — Bocunebart met its primary endpoint in the PROCEED trial, showing a statistically significant reduction in monthly migraine days compared to placebo. Management emphasized its potential as a first-in-class treatment targ...
- Chronic Migraine Market Opportunity — Management highlighted the significant unmet need in chronic migraine, with approximately 80 million sufferers globally. Bocunebart aims to address this with a differentiated mechanism, potentially capturing a large segm...
- Regulatory and Phase III Plans — Lundbeck plans to engage with regulators to discuss Phase III trial designs, focusing on chronic migraine patients. The company aims to initiate Phase III trials in the second half of 2026.
- Pipeline and R&D Strategy — The success of Bocunebart is seen as a validation of Lundbeck's R&D transformation strategy, which has focused on innovative and differentiated mechanisms.
Read the full H. Lundbeck A/S transcript (June 5, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About H. Lundbeck A/S
H. Lundbeck A/S (HLUNB) is a publicly listed company in the Pharmaceuticals industry, within the Health Care sector. It trades on CPSE and is based in DK. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 42 calls on record spanning January 15, 2020 to June 5, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 42 H. Lundbeck A/S earnings call transcripts on record, spanning January 15, 2020 to June 5, 2026. Based on this history, H. Lundbeck A/S reports quarterly. The most recent call on file is dated June 5, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- HLUNB
- Exchange
- CPSE
- Country
- DK
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Calls on record
- 42
- First call
- January 15, 2020
- Most recent
- June 5, 2026
- Reporting cadence
- quarterly